Enthera Pharmaceuticals is a company that develops a biotechnology platform designed to find new therapeutic approaches to treat diabetes and related gastrointestinal complication. Its platform validates the role of the hormone IGFBP3 in intestinal diseases, enabling doctors and healthcare professionals to pave the way for medical treatment for diabetes and its complications.